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IMPORTANCE Iron deficiency is present in approximately 50% of patients with heart failure
with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of
reduced functional capacity andmortality. However, the efficacy of inexpensive readily
available oral iron supplementation in heart failure is unknown.
OBJECTIVE To test whether therapy with oral iron improves peak exercise capacity in patients
with HFrEF and iron deficiency.
DESIGN, SETTING, AND PARTICIPANTS Phase 2, double-blind, placebo-controlled randomized
clinical trial of patients with HFrEF (<40%) and iron deficiency, defined as a serum ferritin
level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mLwith transferrin
saturation of less than 20%. Participants were enrolled between September 2014 and
November 2015 at 23 US sites.
INTERVENTIONS Oral iron polysaccharide (n = 111) or placebo (n = 114), 150mg twice daily for
16 weeks.
MAIN OUTCOMES ANDMEASURES The primary end point was a change in peak oxygen uptake
(V˙O2) from baseline to 16 weeks. Secondary end points were change in 6-minute walk
distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health
status as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, range 0-100, higher
scores reflect better quality of life).
RESULTS Among 225 randomized participants (median age, 63 years; 36%women) 203
completed the study. Themedian baseline peak V˙O2 was 1196mL/min (interquartile range
[IQR], 887-1448mL/min) in the oral iron group and 1167mL/min (IQR, 887-1449mL/min)
in the placebo group. The primary end point, change in peak V˙O2 at 16 weeks, did not
significantly differ between the oral iron and placebo groups (+23mL/min vs −2mL/min;
difference, 21 mL/min [95% CI, −34 to +76mL/min]; P = .46). Similarly, at 16 weeks, there
were no significant differences between treatment groups in changes in 6-minute walk
distance (−13 m; 95% CI, −32 to 6m), NT-proBNP levels (159; 95% CI, −280 to 599 pg/mL),
or KCCQ score (1; 95% CI, −2.4 to 4.4), all P > .05.
CONCLUSIONS AND RELEVANCE Among participants with HFrEFwith iron deficiency,
high-dose oral iron did not improve exercise capacity over 16 weeks. These results do not
support use of oral iron supplementation in patients with HFrEF.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02188784
JAMA. 2017;317(19):1958-1966. doi:10.1001/jama.2017.5427
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I ron deficiency is themost commonnutritional deficiencyworldwide, affectingmore than 15% of the global popula-tionasof20101andapproximatelyone-halfofpatientswith
symptomatic heart failure.2 Thepresenceof irondeficiency in
patients with heart failure, regardless of hemoglobin status,
is associated with reduced functional capacity, poorer qual-
ity of life, and increased mortality.2,3
Iron plays a critical role in systemic oxygen (O2) delivery
andutilization.3-6 Ironcontributes toerythropoiesis and there-
fore irondeficiencydecreasesO2-carryingcapacityof theblood
through reduced hemoglobin levels. Iron is also an obligate
component of enzymes involved in cellular respiration, oxi-
dativephosphorylation,vascularhomeostasis,nitricoxidegen-
eration, and the citric acid cycle.7,8 Hence, cells with high-
energydemands, including skeletal andcardiacmyocytes, are
particularly sensitive todepleted iron stores.9Cardiac ironde-
ficiency is present in patients with heart failure and associ-
ated with impaired mitochondrial function,10 abnormal sar-
comerestructure,5 and leftventricular systolicdysfunction.11,12
Despite growing recognition of the functional and prog-
nostic significance of iron deficiency, randomized multi-
center trials exploring the utility of oral iron supplementa-
tion, a therapy that is inexpensive, readily available, and safe,
havenot beenperformed inpatientswithheart failure.More-
over, patient characteristics andbiochemical profiles thatmay
influence responsiveness tooral iron inpatientswithheart fail-
urehavenotbeendefined.Althoughresultsof intravenous iron
repletion trials have been favorable,13,14 regularly treating pa-
tients with intravenous iron products is expensive and poses
logistical challenges for outpatients. The Iron Repletion Ef-
fects on Oxygen Uptake in Heart Failure (IRONOUT HF) trial
was designed to test the hypothesis that, comparedwith pla-
cebo, oral iron repletion in heart failure patientswith iron de-
ficiency improves exercise capacity after 16weeks of therapy.
Methods
Study Oversight
All studyparticipantsprovidedwritten informedconsentprior
to enrollment. TheNationalHeart, Lung, andBlood Institute–
sponsoredHeart FailureClinical ResearchNetwork investiga-
tors conceived, designed, and conducted this study. The trial
protocol was approved by a National Heart, Lung, and Blood
Institute–appointed protocol review committee and data and
safetymonitoring board andby the institutional reviewboard
at each participating site. The Duke Clinical Research Insti-
tute served as the coordinating center.
Study Design
The rationale and design of this study have been previously
described15andarereportedinthefullprotocol (seeSupplement
1).Patientswithreducedleftventricularejectionfraction(≤40%)
and heart failure (with New York Heart Association functional
class II through IV symptoms) (HFrEF) who were stable while
receivingmedical therapywereeligible toparticipate if theyhad
objective evidence of iron deficiency (ferritin 15-100 ng/mL or
between100-299ng/mLwithatransferrinsaturation[Tsat] level
<20%) and hemoglobin levels between 9 and 15 g/dL (men) or
9 and 13.5 g/dL (women).15 Individualswere excluded if a neu-
romuscular, orthopedic, or other noncardiac condition pre-
vented cardiopulmonary exercise testing (CPET). Inability to
achievea respiratoryexchange ratiogreater thanorequal to 1.0
on baseline screening CPET was also an exclusion criterion.
Acomplete listof thetrial inclusionandexclusioncriteria ispro-
vided in eTable 1 in Supplement 2.
Race, ethnicity, and sex were included as data elements
to satisfy theNationalHeart, Lung, andBlood Institute Policy
for Inclusion of Women and Minorities in Clinical Research.
Race, ethnicity, and sex determinationswere provided by the
participants andcollectedas fixedcategories. CPETswereper-
formed by CPET Core Laboratory–certified sites using equip-
ment and calibration approaches that met American Tho-
racic Society standards. CPETswere performed using a 10-W/
min incremental ramp protocol, and breath-by-breath
measures of oxygen uptake were uniformly analyzed by the
CPET Core Laboratory. Quality controlmeasures included re-
peated physiologic calibration testing individualswho tested
within the normal range to ensure proper equipment calibra-
tion and performance. Participants who met screening crite-
riaunderwentbaseline studies, includingobtainmentofmedi-
cal history and physical examination, CPET, Kansas City
CardiomyopathyQuestionnaire (KCCQ),16 6-minutewalk test,
and phlebotomy for biomarkers, andwere then randomly as-
signed in a 1:1 ratio to receive either oral iron polysaccharide
or placebo with the use of an automated web-based system.
A permuted block-randomization method (4 participants/
block) was stratified by enrolling site and anemia status (de-
fined as hemoglobin <12 g/dL).
Studydrugwas administeredorally at 150mg, twicedaily
for 16weeks. At the endof 8weeks,medical historywas again
recorded and participants underwent a physical examina-
tion, a 6-minute walk test, and completed a KCCQ quality of
life questionnaire. At the end of 16 weeks, each participant's
medical history, physical examination, KCCQ, CPET, and
6-minute walk test were repeated in the same order. If ad-
verse effects developed, study personnel could recommend
a discontinuation of the study drug or a dose frequency re-
duction to once daily. Blinded central core laboratories as-
sessedbiomarkers (UniversityofVermont)andCPETendpoints
(Massachusetts General Hospital, Harvard University).
Key Points
Question Does therapy with oral iron improve exercise capacity in
patients with heart failure and iron deficiency?
Findings In this randomized clinical trial of 225 adults with heart
failure and reduced ejection fraction, oral iron polysaccharide
minimally repleted iron stores and had no significant effect on
exercise capacity at 16 weeks compared with placebo (+23mL/min
for oral iron polysaccharide vs −2mL/min for placebo).
Meaning These findings do not support the use of oral iron
supplementation in patients with heart failure and reduced left
ventricular ejection fraction and iron deficiency.
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Study End Points
The primary end pointwas the change in peak oxygen uptake
(peak V˙ O2) after 16 weeks of therapy. Change in peak V˙ O2 re-
flects themultiplemechanisms bywhich iron repletion is ex-
pected to improve systemic oxygen delivery and utilization
(previouslydescribed).15There isalsosignificant intrinsicvalue
to patients in improving impaired exercise capacity, a cardi-
nal manifestation of heart failure.
Secondary end points included assessments of (1) sub-
maximal exercise capacity, as measured by O2 uptake kinet-
ics at initiationof exercise17; (2) ventilatory efficiency, asmea-
sured by minute ventilation relative to CO2 production
throughout exercise; (3) 6-minute walk distance; (4) plasma
N-terminal pro-B-type natriuretic peptide (NT-proBNP) lev-
els; and (5) KCCQ. Exploratory objectives sought to deter-
mine if the followingprespecified subgroupsofpatientswould
derive differential benefit from oral iron: (1) patients with or
without anemia; (2) patients with or without venous conges-
tion based on jugular venous pressure (>10 cm) or lower ex-
tremity edema; and (3) patients with and without a respira-
tory exchange ratio greater than 1.1 during both maximum
incremental exercise tests. Other exploratory objectiveswere
used to examinewhether oral iron repletion influenced clini-
cal outcomes: time to death, time to heart failure hospitaliza-
tion, O2 uptake at the ventilatory threshold, and renal func-
tion(creatinine,cystatinC). Ironstudies (iron, total ironbinding
capacity, and ferritin) weremeasured at baseline and after 16
weeks of study medication to determine the extent to which
oral iron led to iron repletion in HFrEF patients.
Hepcidin is a hepatically derived peptide that inhibits in-
testinal iron absorption by interacting with its specific trans-
membranereceptor(ferroportin)ontargetcells.Hepcidincauses
reducedexpressionof ferroportin,which is responsible for im-
portingsystemicironfromenterocytesandalsoironreleasefrom
thereticuloendothelial system.18-21An iron-repletestate stimu-
lates hepcidin expression and reduces iron absorption. Iron
depletion suppresses hepcidin levels and enhances iron ab-
sorption. Inflammationcanalso inducehepcidinexpression in-
dependent of iron stores and thus, inappropriately limit iron
absorption.22 Because heart failure is associated with in-
creased inflammation, predisposing to hepcidin dysregula-
tion, this study sought to determine if baseline hepcidin levels
predicted oral iron responsiveness. In addition, we measured
soluble transferrin receptor levels because elevated levels are
observed in states of high cellular avidity for iron, butwhether
levels normalizewith oral iron repletion is unknown.18 There-
foreplasmahepcidin levelsandsoluble transferrin receptor lev-
elsweremeasuredatbaselineandafter 16weeks togainmecha-
nistic insight into oral iron responsiveness in heart failure.
Statistical Analysis
Thefull statisticalanalysisplanappears inSupplement3.Allpri-
mary analyses were based on the intention-to-treat principle,
meaning that study participantswere analyzed asmembers of
the treatmentgrouptowhich theywere randomizedregardless
oftheiradherencetoorreceiptoftheintendedtreatment.Amini-
mally important difference for peak V˙ O2 of 1.0mL/kg/minwas
usedbasedonapreviouslydeterminedsignificant relationship
between that change inpeakV˙ O2 andheart failureoutcomes.23
Using an estimate of 2.0mL/kg/min for the standarddeviation
forpeakV˙ O2,asamplesizeof172participants (86pergroup)pro-
vided90%power todetect theminimally importantdifference
witha2-sided type Ierrorof .05.Allowing for20%missingdata
(toaccountfordeath,studywithdrawal,ormissingdata)resulted
in a sample size of at least 108 per group.
Baseline data are presented as medians with interquartile
ranges (IQRs). A general linear model with the change in peak
V˙ O2measured at 16weeks as the response variable andpredic-
tor variables including a treatment indicator and the baseline
measureofpeakV˙ O2wereused in theprimaryanalysis.Thepri-
mary analysis for peak V˙ O2 used multiple imputation tech-
niques to address incomplete data (statistical analysis plan in
Supplement 3). A sensitivity analysis of the peak V˙ O2 outcome
used values from participants with complete data at baseline
and 16weeks. Amixed-effects model was used to analyze site
effects for the primary end point. For primary and secondary
endpoints,P values less than .05were considered statistically
significantwith 2-sided significance testing. All analyseswere
conducted using SAS statistical software, version 9.4.
Results
A total of 225 participants were enrolled (Figure 1) in the trial
fromSeptember3,2014, throughNovember 18,2015,at23sites
in the United States. Baseline characteristics are presented in
Table 1. The median age was 63 years and 36% of the partici-
pants were women. Median duration of heart failure was 5.7
years. IschemicheartdiseasewastheprimaryetiologyofHFrEF
in 78% of participants. Despite high rates of guideline-
directedmedical therapies forHFrEF, themedianNT-proBNP
Figure 1. Flow of Participants for the IRONOUTHF Study
225 Patients randomizeda
111 Included in the primary analysis 114 Included in the primary analysis
111 Randomized to receive iron
polysaccharide
111 Received at least 1 dose
 of iron polysaccharide
114 Randomized to receive placebo
113 Received at least 1 dose
 of placebo
1 Did not receive placebo
(physician decision)
96 Completed the study per protocol
15 Did not complete the study per
protocol (iron polysaccharide
discontinued prior to end
of study)
6 Incomplete exercise data for
primary endpoint (peak V• O2)
assessment
3 Withdrew consent
3 Died
3 Other
95 Completed the study per protocol
19 Did not complete the study per
protocol (placebo discontinued
prior to end of study)
6 Incomplete exercise data for
primary endpoint (peak V• O2)
assessment
9 Withdrew consent
3 Other
1 Died
Secondary end points were analyzed with multiple imputation techniques when
data were unavailable for the end point.
a Data on patients screened for eligibility were not available.
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Table 1. Baseline Characteristics of Participants in the IRONOUTHF Studya
Oral Iron
(n = 111)
Placebo
(n = 114)
All
(N = 225)
Age, median (IQR), y 63.0 (54-71) 63 (55-70) 63 (55-70)
Women 44 (40) 36 (32) 80 (36)
Race/ethnicityb
White 79 (71) 85 (75) 164 (73)
Black 31 (28) 26 (23) 57 (25)
Asian 1 (1) 2 (2) 3 (1)
More than 1 race 0 1 (1) 1 (1)
Body mass index, median (IQR)c 28.9 (25.3-33.7) 29.6 (25.9-33.8) 29.2 (25.7-33.8)
Left ventricular ejection fraction, median (IQR), % 25 (20-34) 25 (20-33) 25 (20-34)
Functional Measures
New York Heart Association classification
II 81 (73) 69 (61) 150 (67)
III 30 (27) 45 (39) 75 (33)
Summary score, median (IQR)d
KCCQ clinical score 77.1 (63.5-89.6) 74.2 (58.3-87.5) 75.5 (61.5-88.5)
KCCQ overall score 75.0 (59.6-87.3) 70.1 (50.8-85.4) 71.9 (56.0-85.9)
6-min walk distance, median (IQR), m 365 (304-433) 360 (273-428) 363 (292-428)
Physical examination
Weight, median (IQR), kg 86 (71-100) 90 (76-105) 90 (75-103)
Systolic blood pressure, median (IQR), mm Hg 112 (100-125) 112 (98-125) 112 (98-125)
Heart rate, median (IQR), beats/min 70 (64-77) 73 (64-80) 71 (64-79)
Elevated jugular venous pressure 13 (12) 13 (11) 26 (12)
Peripheral edema 14 (13) 9 (8) 23 (10)
Medical history
Time since diagnosis of heart failure, median (IQR), y 5.3 (1.4-10.3) 6.2 (2.0-9.8) 5.7 (1.9-10.0)
Prior hospitalization for heart failure within past year 46 (41) 51 (45) 97 (43)
Ischemic heart disease 86 (77) 89 (78) 175 (78)
Hypertension 80 (72) 82 (73) 162 (72)
Atrial fibrillation 43 (39) 43 (38) 86 (39)
Diabetes mellitus 38 (34) 50 (44) 88 (39)
Stage ≥3 chronic kidney diseasee 21 (19) 31 (27) 52 (23)
Heart failure medications at enrollment
β-Blocker 106 (95) 110 (96) 216 (96)
ACE inhibitor or ARB 98 (88) 91 (80) 189 (84)
Loop diuretic 96 (86) 89 (79) 185 (83)
Antiplatelet agent 74 (67) 79 (69) 153 (68)
Aldosterone antagonist 68 (61) 68 (60) 136 (60)
Anticoagulant agent 55 (50) 49 (43) 104 (46)
Digoxin 23 (21) 27 (24) 50 (22)
Long-acting nitrates 21 (19) 25 (22) 46 (20)
Hydralazine 15 (14) 18 (16) 33 (15)
Laboratory measurements, median (IQR)
Creatinine, mg/dL 1.3 (1.0-1.6) 1.2 (0.9-1.5) 1.2 (1.0-1.5)
Cystatin C, mg/L 1.1 (0.9-1.3) 1.1 (0.8-1.3) 1.1 (0.8-1.3)
NT-proBNP, pg/mLf 1072 (413-2286) 1170 (527-2530) 1111 (453-2412)
Hemoglobin, g/dL 12.6 (11.7-13.3) 12.7 (11.8-13.4) 12.6 (11.8-13.3)
Iron, μg/dLf 71 (59-89) 72 (53-94) 62 (51-78)
Total iron-binding capacity, μg/dLf 383 (350-434) 370 (336-415) 349 (305-392)
Ferritin, ng/mLf 75 (43-108) 70 (42-111) 69 (40-98)
Transferrin saturation, %f 19 (16-24) 20 (14-26) 18 (15-22)
Soluble transferrin receptor, mg/Lf 3.9 (3.2-4.8) 3.8 (2.9-4.8) 3.8 (3.1-4.8)
Hepcidin, ng/mLf 6.7 (3.4-11.3) 7.4 (3.6-11.6) 7.0 (3.5-11.4)
(continued)
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level at the timeof enrollmentwas 1111 (IQR, 453-2412) pg/mL
and themedian left ventricular ejection fractionwas25%(IQR,
20%-34%).Exercise capacitywas reducedasevidencedbyme-
dian peak V˙ O2 of 13.2 (IQR, 11.1-15.7) mL/kg/min. Venous con-
gestionwas uncommon as only 12% of participants had jugu-
lar venous pressure elevation on examination, and 10% of
participants had at least mild peripheral edema. In the set-
tingof low ferritin levels (median, 69ng/mL [IQR,40-98]) and
lowTsat levels (median, 18% [IQR, 15%-22%]),medianhemo-
globin levelswere reduced at 12.6 (IQR, 11.8-13.3) g/dL. Levels
of soluble transferrin receptors, which increase during states
of iron deficiency and high cellular avidity for iron, were el-
evatedwith amedian value of 3.8 (IQR, 3.1-4.8)mg/L. Plasma
levels of the iron regulatory peptide hepcidin were also el-
evated with a median value of 7.0 (IQR, 3.5-11.4) ng/mL. Use
of antiplateletdrugs (68%)andanticoagulants (46%)wascom-
mon. There was no important differences in any of the base-
line clinical, laboratory, or CPET characteristics between par-
ticipants in the 2 treatment groups.
At least 1 doseof studymedicationwas receivedbyall par-
ticipants randomized to receiveoral ironand 113of the 114par-
ticipants randomized to receiveplacebo (Figure 1). Frequency
of permanent study drug discontinuation prior to study ter-
mination were similar in the oral iron group (14%; 15 partici-
pants) and the placebo group (15%; 17 participants) (Figure 1),
and thehazard ratio for time topermanent studydrugdiscon-
tinuation (0.90 favoringoral iron [95%CI,0.45 to 1.79];P = .76)
did not significantly differ between groups.
Primary End Point
The median baseline peak V˙ O2 was 1196 mL/min (IQR, 887 to
1448mL/min) in theoral irongroupand1167mL/min (IQR,887
to1449mL/min) in theplacebogroup(Table1).Theprimaryend
point, change in peak V˙ O2, did not differ between groups
(oral iron, +23 mL/min [95% CI, −84 to 142 mL/min] vs pla-
cebo, −2mL/min [−110 to 104mL/min]),with abetween-group
difference of 21 mL/min (95% CI, [−34 to 76mL/min]; P = .46;
Table 2). Themean treatment difference in peak V˙ O2 between
oral iron and placebo was 0.3 mL/kg/min (95% CI, −0.27 to
0.87 mL/kg/min; P = .30) when peak V˙ O2 was normalized to
bodyweight.Between-groupdifferences inchange inpeakV˙ O2
remainednonsignificant after adjustment for site effectsusing
mixed-effects modeling (oral iron, + 23 mL/min [95% CI, −28
to75];P = .37)andwithsensitivityanalysesusingcompletecases
(oral iron, +23mL/min [95%CI, −33 to 80]; P = .42) andworst-
rank analyses (oral iron, 108 vs placebo, 95,with higher values
indicatinggreaterpositivechange inpeakV˙ O2 [P = .46]). Inpre-
specified subgroup analyses, the change in peak V˙ O2 was not
significantly different between treatment groups in men vs
women, participants with or without hemoglobin level of less
than 12 g/dL in women and of less than 13.5 g/dL in men, par-
ticipants with or without baseline venous congestion, or par-
ticipants with and without peak respiratory exchange ratios
greater than 1.1 (a threshold indicative of maximum volitional
effort)24 on baseline and 16-week CPETs (eFigure 1 in
Supplement 2).
Secondary End Points and Safety
At 16 weeks, there were no significant differences between
treatment groups in change in6-minutewalkdistance (differ-
ence, −13 m [95% CI, −32 to 6 m]; P = .19), NT-proBNP levels
(159pg/mL[−280to599pg/mL];P = .48),KCCQscore (1.0 [−2.4
to 4.4]; P = .57), O2 uptake kinetics (3 s [−2 to 8 s]; P = .19), or
ventilatory efficiency, as indicatedby the slopeofminuteven-
tilation relative to carbondioxide elimination (VE/VCO2 slope,
0.8 [−0.3 to 2.6]; P = .35). The rates of serious adverse events
observedwith oral iron and placebowere similar, as reported
inTable 2 and ineFigure2 andeTable 2 in Supplement 2. Time
to first adverse event did not differ between groups (hazard
ratio, 0.85 favoring oral iron [95% CI, 0.56-1.31]; P=.47).
Exploratory End Points
At 16 weeks, when compared with placebo, oral iron was as-
sociated with an increment in V˙ O2 at the ventilatory thresh-
old that was not statistically significant (+36.4 mL/min [−3.4
to 76.2mL/min];P = .07). Therewerenodifferences in change
Table 1. Baseline Characteristics of Participants in the IRONOUTHF Studya (continued)
Oral Iron
(n = 111)
Placebo
(n = 114)
All
(N = 225)
CPET Measurements, Median (IQR)
Peak oxygen uptake, V˙O2, mL/min 1196 (887-1448) 1167 (887-1449) 1172 (887-1449)
Peak oxygen uptake, V˙O2, mL/kg/min 13.3 (11.4-15.8) 12.9 (10.5-15.6) 13.2 (11.1-15.7)
Peak respiratory exchange ratio 1.1 (1.1-1.2) 1.1 (1.1-1.2) 1.1 (1.1-1.2)
Ventilatory efficiency, VE/VCO2 slope 35 (29-40) 33 (30-39) 34 (30-40)
Mean response time, O2 uptake kinetics, s 50 (43-58) 47 (40-58) 48 (43-58)
Ventilatory threshold, mL/min 675 (509-841) 703 (580-853) 695 (540-852)
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II
receptor blocker; CPET, cardiopulmonary exercise test; IQR, interquartile range;
KCCQ, Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; VE/VCO2, minute ventilation/carbon dioxide
elimination; V˙O2, oxygen uptake.
SI conversion factors: To calculate creatinine to μmol/L, multiply by 88.4;
ferritin to pmol/L, multiply by 2.247; iron and iron-binding capacity to μmol/L,
multiply by 0.179; hepcidin to nM, multiply by 0.358.
a Data are reported as No. (%) unless otherwise indicated.
bRace and ethnicity were self-reported.
c Calculated as weight in kilograms divided by height in meters squared.
dHigher scores indicate better function (range, 1-100).
e Determined by enrollment site.
f Determined by a central core laboratory. Normal reference ranges: iron,
60-170 μg/dL; total iron binding capacity, 240-450 μg/dL; ferritin,
100-300 ng/mL; transferrin saturation, 20%-50%; soluble transferrin
receptor, 0.9-2.3 mg/L; and hepcidin, <6 ng/mLwhen iron deficient.
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in renal function between groups: creatinine (−0.02 mg/dL
[−0.09to0.05mg/dL];P = .65)andcystatinC(0.03mg/L[−0.01
to 0.08 mg/L]; P = .12).
Iron Bioavailability
Measures of exercise capacity (peak V˙ O2 [r = 0.17; P = .01];
6-minute walk distance [r = 0.28; P < .001]), NT-proBNP
(r = −0.16;P = .02),andKCCQClinicalSummaryscore (r = 0.28;
P < .001)wereall correlatedwithbaselineTsat levels (18%[IQR,
15% to 22%]).
Compared with placebo, oral iron increased Tsat levels
(+3.3% [95% CI, 1.1% to 5.4%]; P = .003) and ferritin levels
(+11.3ng/mL [−0.3 to22.9ng/mL];P = .06) (Table 3 andeTable
2 in Supplement 2). Levels of soluble transferrin receptors de-
creased in participants treatedwith oral ironwhen compared
with placebo (−0.3mg/L [95% CI, −0.6 to −0.1 mg/L]; P = .01,
Table3).Participants in thehighestquartileof response inTsat,
in response to oral iron, demonstrated improvement inKCCQ
clinical summary scores (5.2 [95% CI, 0.1 to 10.4]; P = .047),
andan increase inV˙ O2 at theventilatory threshold (58mL/min
[95% CI, −7 to 123mL/min]; P = .08) that was not statistically
significant. Changes in peak V˙ O2 (r = 0.16; P = .03) and in
NT-proBNP (r = −0.18;P = .02) correlateddirectlywith change
in Tsat.
Table 3. Levels of IronMetabolismMarkers According to Treatment Group
Iron Indexes
Median (95% CI)
Difference in Change
From Baseline
(95% CI) P Value
Week-16 Values Change From Baseline to Week 16
Oral Iron Placebo Oral Iron Placebo
Iron, μg/dL 80 (59 to 99) 72 (58 to 90) 6 (−12 to 29) 1 (−23 to 18) 11.0 (2.8 to 19.1) .009
TIBC, μg/dL 371 (336 to 405) 374 (339 to 428) −12 (−43 to 5) −0.5 (−22 to 17) −13.4 (−22.2 to −4.6) .003
Tsat, % 22 (16 to 28) 20 (15 to 25) 2 (−3 to 7) 0 (−5 to 5) 3.3 (1.1 to 5.4) .003
Ferritin, ng/ml 95 (58 to 134) 75 (42 to 123) 18 (−8 to 38) 1 (−15 to 17) 11.3 (−0.3 to 22.9) .06
Hepcidin, ng/ml 8.9 (5.0 to 14.3) 7.8 (4.2 to 12.7) 1.7 (−1.0 to 5.6) −0.3 (−3.2 to 3.1) 1.5 (−0.6 to 3.7) .17
sTfR, mg/L 3.7 (2.9 to 4.4) 3.9 (3.1 to 4.8) −0.3 (−0.8 to 0.1) 0.0 (−0.5 to 0.4) −0.3 (−0.6 to −0.1) .01
Abbreviations: sTfR, soluble transferrin receptor; TIBC, total iron binding capacity; Tsat, transferrin saturation.
Table 2. Primary, Secondary, and Safety End Points
Median (IQR)
Difference in Change
From Baseline
(95% CI) P Value
Week-16 Valuesa Change From Baseline to Week 16
Oral Iron Placebo Oral Iron Placebo
Primary End Point
Peak V˙O2 at 16 wk, mL/min 1218 (892 to 1500) 1187 (902 to 1425) 23 (−84 to 142) −2 (−110 to 104) 21 (−34 to 76) .46
Ppeak V˙O2 at 16 wk, mL/kg/min 13.5 (11.7 to 16.3) 13.0 (10.2 to 15.9) 0.20 (−1.1 to 1.6) 0.01 (−1.1 to 0.9) 0.30 (−0.27 to 0.87) .30
Secondary End Points
6-Min walk distance
at 8 wk, m
380 (322 to 467) 376 (286 to 448) 15 (−17 to 55) 21 (−24 to 56) −1 (−24 to 23) .95
6-Min walk distance
at 16 wk, m
366 (315 to 456) 397 (299 to 472) 19 (−19 to 51) 32 (−12 to 66) −13 (−32 to 6) .19
Mean response time
(O2 uptake kinetics), s
52 (46 to 61) 47 (40 to 58) 2.5 (−7 to 9) 1 (−10 to 6) 3 (−2 to 8) .19
Ventilatory efficiency
(VE/VCO2 slope)
34.8 (29.9 to 41.1) 33.5 (29.4 to 38.9) −0.3 (−3.0 to 2.1) −0.3 (−4.6 to 2.8) 0.8 (−0.3 to 2.6) .35
NT-proBNP, pg/mL 889 (376 to 2373) 1085 (447 to 2582) 4 (−342 to 288) −37 (−412 to 363) 159 (−280 to 599) .48
KCCQ clinical summary score
at 8 wkb
81.3 (70.8 to 91.7) 75.0 (58.9 to 87.5) 5.2 (−2.1 to 12.5) 1.0 (−7.3 to 8.3) 3.4 (−0.4 to 7.2) .08
KCCQ clinical summary score
at 16 wkb
80.7 (67.7 to 91.6) 77.1 (65.1 to 89.6) 3.1 (−4.2 to 13.5) 3.0 (−4.2 to 10.4) 1.0 (−2.4 to 4.4) .57
Exploratory End Points
Ventilatory threshold
at 16 wk, mL/min
685 (546 to 884) 714 (558 to 873) 22 (−49 to 127) −2 (−86 to 75) 36 (−3 to 76) .07
Creatinine at 16 wk, mg/dL 1.31 (1.01 to 1.56) 1.21 (0.90 to 1.49) 0.03 (−0.10 to 0.13) 0.00 (−0.10 to 0.11) −0.02 (−0.09 to 0.05) .65
Cystatin C at 16 wk, mg/L 1.06 (0.86 to 1.38) 1.02 (0.78 to 1.31) 0.02 (−0.04 to 0.09) 0.01 (−0.08 to 0.07) 0.03 (−0.01 to 0.08) .12
Safety End Points, No. (%) Oral Iron Placebo OR (95% CI)
Adverse events 39 (35) 45 (39) 0.83 (0.48 to 1.43) .50
Serious adverse events 11 (10) 10 (9) 1.14 (0.47 to 2.81) .77
Permanent study drug discontinuation 15 (14) 17 (15) 0.90 (0.45 to 1.79) .76
Death or cardiovascular rehospitalization 14 (13) 12 (11) 1.19 (0.55 to 2.59) .64
Abbreviations: IQR, interquartile range; KCCQ, Kansas City Cardiomyopathy;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; OR, odds ratio; V˙O2,
volume of oxygen uptake.
a Values are for measurements made at week 16 unless otherwise specified for
8 weekmeasurements.
bHigher scores indicate improved clinical status (range, 1-100).
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Responders to Oral Iron Therapy
Median hepcidin levels increased from 6.7 to 8.9 ng/mL
(+1.7 ng/mL [95% CI, −1.0 to 5.6 ng/mL]; P = .007) in the oral
iron group, consistent with the anticipated response to in-
creased iron exposure, and remained unchanged in the pla-
cebo group (7.4 to 7.8 ng/mL; −0.3 ng/mL [95% CI, −3.2 to
3.1ng/mL];P = .91). Thebetween-groupcomparisonof change
inhepcidin levelswasnot statistically significant (+1.5 ng/mL
[95% CI, −0.6 to 3.7 ng/mL]; P = .17 [Table 3]).
In response to 16 weeks of oral iron across quartiles of
increasing baseline hepcidin levels, there were reduced in-
crements in Tsat and ferritin and a blunted fall in soluble
transferrinreceptor levels (Figure2).Changes inTsat (r = −0.29;
P = .004), ferritin (r = −0.30; P = .004), and soluble transfer-
rin receptor levels (r = 0.48; P < .001) at 16weekswere corre-
lated with baseline hepcidin levels.
Discussion
High-dose oral iron did not improve exercise capacity in
patients with iron deficiency and HFrEF. The lack of effect of
oral iron on exercise capacity, including peak V˙ O2 and
6-minute walk distance, and quality of life scores (KCCQ)
stands in contrast to results from trials of intravenous iron
repletion in similar patient populations.13,14,25 Also in con-
trast to previous studies with intravenous iron repletion, in
this study, oral iron therapy produced minimal improvement
in iron stores, implicating the route of administration rather
than the strategy of iron repletion in the lack of clinical ben-
efit. The significant relationship between higher baseline
hepcidin levels and lack of iron repletion provides mechanis-
tic insight into this study’s observed findings.
With the exception of one study that included 7 individu-
als randomized to receive oral iron,26 this is the first multi-
center randomizedclinical trial exploring theutilityoforal iron
supplementation in HFrEF patients with iron deficiency. In
light of the failure of oral iron to improve measures of func-
tional capacity in this study, a comparisonof thepatientpopu-
lations and relative changes in iron stores to trials of intrave-
nous iron repletion is warranted.
The patient population in this study was similar to that
investigated in trials of intravenous iron repletion (FAIR-HF
[Ferinject Assessment in Patients With Iron Deficiency and
Chronic Heart Failure] and CONFIRM-HF [Ferric Carboxy-
maltose Evaluation on Performance in Patients With Iron
Deficiency in Combination with Chronic Heart Failure])13,14
in patient age and body mass index, as well as underlying
heart failure etiology and baseline pharmacotherapy. In
addition, baseline laboratory indices of iron stores were
similar across the 3 studies. However, iron indices following
oral repletion, as compared with intravenous iron repletion,
differed markedly (eTable 3 in Supplement 2). Despite
administering approximately 15-fold more iron orally in this
study than that administered intravenously in FAIR-HF
(ie, 33.6 g vs ≈ 2 g), there was only a modest 3%-median
increment in Tsat and 11-ng/mL increment in ferritin in par-
ticipants randomized to receive oral iron vs placebo in this
study, compared with a 70%-median increment in Tsat and
a 550%-increment in ferritin with intravenous iron adminis-
tration in the FAIR-HF Trial.13
There are several potential explanations for failure of oral
iron to improve iron stores and exercise capacity in this trial.
Hepcidin plays a critical role in inhibiting iron absorption.18-21
In this study, participants with higher baseline hepcidin lev-
els demonstrated reduced Tsat and ferritin augmentation and
an attenuated decline in soluble transferrin receptor levels in
response to 16 weeks of oral iron supplementation (Figure 2).
Taken together, these findings indicate that higher hepcidin
levels may limit responsiveness to oral iron. Expected hepci-
din levels in individuals with iron deficiency and anemia are
lower than the values measured in this study.27,28
Figure 2. Relationships BetweenQuartiles of Baseline PlasmaHepcidin Levels and Response in Participants TreatedWith Iron Polysaccharide
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Other potential mediators of refractoriness to oral iron in
heart failure seem less likely to have affected our findings. Use
ofanticoagulantsandantiplatelet agentswasprevalent,but the
rateofexpected lossof iron(1-1.5mg/d) ismarkedly less thanthe
repletion dose (300mg/d) administered. Therefore, in the ab-
sence of overt gastrointenstinal bleeding, which did not occur
in anyof theparticipants treatedwithoral ironduring the trial,
blood loss would not be expected to account for the observed
minimal increases in iron storeswith oral iron treatment.
The choice of iron polysaccharide formulation for this
studywas based on its offering the highest dose of elemental
iron among available oral supplements, coupled with its tol-
erance profile to aid in adherence and minimize risk of un-
blinding participants. Polysaccharide iron preparations have
been shown to provide comparable iron repletion to iron
salts.29-31 Recommended daily oral iron intake is 8 to 18 mg.
Hence, even after accounting for limited gastrointestinal iron
absorption, the 20-fold increase in oral iron exposure, com-
pared with the recommended daily intake, served to ad-
equately test the hypothesis that oral iron supplementation
would improve iron stores and functional capacity in HFrEF.
The low incidenceoforal irondiscontinuation,whichwas 14%
amongparticipants receiving ironand15%intheplacebogroup,
argues against the observed findings being related to lack of
adherence with oral iron.
The selection of change in peak V˙ O2 for the primary end
point, aspreviouslydescribed,15wasbasedonthefact thatpeak
V˙ O2 is thegoldstandard indicatorof functionalcapacity inheart
failure and has been shown to improve with iron repletion in
non–heart failure populations. The lackof treatment effect on
quality of life,NT-proBNP, andother physiological endpoints
is consistent with the observed lack of treatment effect on
maximal exercise capacity. Theexploratory endpoint, change
inV˙ O2 at the ventilatory threshold, showed a 5% increment in
the iron group and no change in placebo, although the study
may have been underpowered for this modest between-
group difference to reach significance (P = .08). Submaxi-
mumexercise capacity, indicative of endurance and indepen-
dent of volitional effort, may be more sensitive to subtle
changes in iron bioavailability as opposed to peak V˙ O2.8
Recognition of the high prevalence of iron deficiency
( ≈ 50%) in patients with HFrEF and the consistent clinical
benefit demonstrated in studies with intravenous iron reple-
tion is motivating clinicians to prescribe iron supplementa-
tion. This trial complements recent studies about intrave-
nous iron treatment in informing the appropriate approach
to iron repletion in HFrEF. This study’s findings of minimal
changes in iron stores and lack of effect on peak exercise
capacity suggests that prescription of oral iron in patients
with HFrEF offers no benefit. However, the correlates
observed between baseline iron indices and exercise capac-
ity, as well as changes in Tsat being related to improvement
in peak V˙ O2 are consistent with results of recent trials sug-
gesting beneficial effects of intravenous iron on functional
capacity in HFrEF.
This studyhas some important limitations. This studywas
notpoweredtodetectdifferences inclinicaleventsorsafetyend
points.Therewasalsonodirectcomparisonbetweenintravenous
vsoral iron repletion.Given the relatively short durationof the
trial, it is possible that longer duration or higher dose of expo-
suremayhaveledtomoresignificant improvementinironstores
and increased exercise capacity, particularly among thosepar-
ticipantswithappropriately lowhepcidin levels. Inaddition, this
studywasconfinedtopatientswithHFrEFandfindingsmaydif-
fer in heart failurewith preserved ejection fraction.
Conclusions
Among participants with iron deficiency and HFrEF, high-
dose oral iron minimally augmented iron stores and did not
improveexercisecapacityover 16weeks.These findingsdonot
support the use of oral iron supplementation to treat iron de-
ficiency in patients with HFrEF.
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